XTL BIOPHARMACEUTICALS LTD(XTLB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.5M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
XTLB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for XTL BIOPHARMACEUTICALS LTD (XTLB), a Healthcare sector company. XTLB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.5m in revenue. Based on the latest XBRL financial filings (FY 2024), XTL BIOPHARMACEUTICALS LTD reports quarterly revenue of $451.0K, net income of $-1.0M. Top institutional holders of XTLB by reported 13-F value include SmartHarvest Portfolios,, RHUMBLINE ADVISERS, GAMMA Investing, based on the most recent SEC filings. XTLB trades on the Nasdaq exchange and files with the SEC under CIK 1023549. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XTLB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for XTL BIOPHARMACEUTICALS LTD directly from SEC EDGAR.
Revenue
FY 2024
$451.0K
Net Income
FY 2024
$-1.0M
AI Insight: XTLB Financial Trends
Insufficient financial data to assess trends; all key metrics are missing across the historical record.
• No revenue, profitability, cash flow, or balance sheet figures available for any reported period.
⚠ Data gaps span 2018–2024 with no interim updates; unable to evaluate operational or financial trajectory.
AI Insight: XTLB Ratio Trends
Insufficient financial data to establish meaningful trend analysis for XTLB.
• All key profitability and efficiency ratios are blank across the entire dataset from Q4 2018 through Q4 2024.
⚠ No operational or financial metrics available to assess margin trajectory, cash generation, or capital efficiency.
Get alerted when XTLB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for XTL BIOPHARMACEUTICALS LTD including:
Top Institutional Holders of XTLB
SmartHarvest Portfolios, LLC
$32.2K13,351 shRHUMBLINE ADVISERS
$14.4K5,987 shGAMMA Investing LLC
$8.2K3,388 shTower Research Capital LLC (TRC)
$588.00244 shNoked Israel Ltd
$120.0049,722 shMORGAN STANLEY
$24.0010 sh
| Fund | Value | Shares |
|---|---|---|
| SmartHarvest Portfolios, LLC | $32.2K | 13,351 |
| RHUMBLINE ADVISERS | $14.4K | 5,987 |
| GAMMA Investing LLC | $8.2K | 3,388 |
| Tower Research Capital LLC (TRC) | $588.00 | 244 |
| Noked Israel Ltd | $120.00 | 49,722 |
| MORGAN STANLEY | $24.00 | 10 |
More Healthcare Companies
View all Healthcare →Put XTLB on your watchlist
Track score changes the day XTL BIOPHARMACEUTICALS LTD files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is XTLB a good stock to buy?
13F Pro's AI-powered analysis of XTL BIOPHARMACEUTICALS LTD (XTLB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XTLB are available on the XTLB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own XTLB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XTLB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of XTL BIOPHARMACEUTICALS LTD's investment landscape.